Egg Freezing at NYU Langone Reproductive Specialists of New York | NYU Langone Health
At NYU Langone Reproductive Specialists of New York, we help women, men, and couples preserve their fertility.
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)
This is a phase 3 study, comparing the new medicine called Elacestrant (selective estrogen receptor degrader) with standard hormonal treatments in patients with ER-positive/HER2-negative early breast cancer who have previously received at least 2 years of hormonal treatment after their surgery or first breast cancer treatment and are currently receiving hormonal treatment. Patients will be divided into two groups. One group will receive the study medicine elacestrant, and the other group will continue the standard hormonal treatment they are already receiving. All patients will have their blood samples taken to see how their bodies are handling the medicine. Doctors will perform special scans at different times throughout the study to see how the patients are doing and if the study medicine is working better than the standard treatment. All patients will be closely watched for side effects and will be followed for 28 (+7) days after their last treatment.
Elbow Sprains & Strains | NYU Langone Health
Doctors at NYU Langone diagnose elbow sprains and strains and offer treatments to help you heal.
Electroconvulsive Therapy for Bipolar Disorder | NYU Langone Health
Doctors at NYU Langone may prescribe electroconvulsive therapy for adults with bipolar disorder that does not respond to other treatments.
Electroconvulsive Therapy for Depression | NYU Langone Health
Doctors at NYU Langone may prescribe electroconvulsive therapy for people with severe depression who have not responded to other treatments.
Electroconvulsive Therapy Program at Inpatient Psychiatry at Tisch Hospital | NYU Langone Health
The Electroconvulsive Therapy Program at NYU Langone’s Tisch Hospital provides inpatient and outpatient treatment and care.
Electronic cigarettes as a harm reduction strategy in people living with HIV/AIDS
People living with HIV/AIDS (PLWHA) are known to have exceptionally higher rate of cigarette smoking and very low quit rates compared to the general population. Although a primary rationale for conducting this study is reducing health disparities among PLWHA, there is a potential benefit of the proposed work from a prevention perspective given that combustible cigarette smoking is an independent risk factor for non-adherence to ART and may decrease the effectiveness of HAART (1-5). Smoking-related illnesses are leading causes of non-HIV/AIDS-related deaths among People Living with HIV/AIDS (PLWHA). (6) There are major yet unique barriers to combustible cigarette (CC) cessation among PLWHA.7? Additionally, FDA approved CC cessation medications have not been effective with this population. (8-11) Electronic cigarettes (E-cigarettes) could help people reduce the harm of CC through reductions in number of Cigarettes per Day (CPD) or quitting CC completely by addressing both nicotine and behavioral dependence. (12-14) A harm reduction approach may be more appropriate to use with PLWHA.15 This mixed-methods study’s purpose is to identify barriers and facilitators, as well as assess preliminary effectiveness of e-cigarettes as a harm reduction strategy among PLWHA.
Elizabeth Golden | NYU Langone Health
Elizabeth Golden is the executive vice president for communications, marketing, government and community affairs at NYU Langone.
ELLIPSS: ELucidating the Landscape of Immunoendotypes in Psoriatic Skin and Synovium
The goal of Accelerating Medicines Partnership (AMP) is to better understand and develop new treatments for autoimmune disorders (such as Psoriatic Spectrum Disease (PSD)), and to reduce the time and cost of developing these new treatment options. NYU Langone Health is participating in the AMP Network for PSD.The purpose of this Network study is to better understand joint and skin involvement in patients withautoimmune diseases such as Psoriatic Spectrum Disease. Looking at the different types of cellsfound in people with PSD will help us to better understand what happens when their joints or skinbecome damaged. This study involves genetic testing. If you decide to participate in this study, the study data andstudy samples that we collect from you will be shared with researchers at other AMP sites. Withinfive years, the data and samples will be shared with other researchers in the biomedical communitywho are not participating in AMP. Sharing this data may help to reduce the time and cost ofdeveloping new treatment options. If you don’t want to have genetic testing, or if you don’t want yourstudy data and study samples shared with other investigators, you should not participate in thisstudy.
Elucidating Neural Mechanisms and Sex Differences in Response to Mindfulness Based Stress Reduction in Generalized Anxiety Disorder
Mindfulness-Based Stress Reduction (MBSR) has demonstrated efficacy for Generalized Anxiety Disorder (GAD), yet there remains a major knowledge gap about its neural mechanisms. Neuroimaging studies thus far have mostly focused on the impact of MBSR on structural and resting-state brain changes, and these studies have been predominantly conducted in healthy participants. Core features of GAD, such as ruminative worry, represent dysfunctional emotion regulation strategies that increase bias towards future threat. MBSR success is associated with improved emotion regulation, enhanced attention to the present moment, and non-judgmental acceptance of internal and external cues. Our primary aim is to elucidate neural mechanisms that drive response to MBSR in patients with generalized anxiety disorder (GAD), and to examine the degree to which sex differences in MBSR response are explained by sex differences in these mechanisms. Our overarching hypothesis is that MBSR enhances ‘top-down’ learning and memory capacities that are broad and impact ‘top-down’ as well as ‘instinctual’ abilities (bottom-up) to regulate fear and emotions. We will first study the functional activation of brain regions associated with the fear extinction network (ventromedial prefrontal cortex (vmPFC), hippocampus, and amygdala) as a specific probe of the ‘instinctual’ type of emotion regulation. Second, we will use a novel analytic approach to examine large-scale functional connectivity as a marker of neural plasticity changes (pre- and post-MBSR) trial-by-trial during fear extinction learning across the entire brain, focusing analyses on the default mode network (DMN), frontoparietal network (FPN), and ventral attention network (VAN). Next, we will examine sex differences in MBSR-induced neural changes and their relationship to sex differences in clinical GAD response. Finally, we will use a novel statistical approach to explore whether baseline neural measures can predict MBSR-induced neural changes and clinical symptom reduction to identify likely MBSR responders. Participants will undergo a standardized 2-day fear conditioning and extinction paradigm in the fMRI scanner before and after MBSR or stress education (SE) with primary clinical outcomes at endpoint and 3 month follow-up. This study will deploy rigorous scientific methods with a time and attention control intervention to enable isolation of MBSR’s mechanistic impact on brain regions involved in emotion regulation and clinical response. The unique combination of a focus on a classic anxiety condition with established emotion regulation difficulties implicating target neural circuits, previously demonstrated MBSR efficacy, and sex differences with rigorous fMRI behavioral probes with novel analytic approaches ought to provide major new insights about MBSR mechanisms and sex considerations, moving towards precision medicine that could guide future treatment development research.